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S24 Journal of Thoracic Oncology Vol. 11 No. 2SKRAS driven NSCLC, to identify various potential
mechanisms that may lead to effector T cell suppres-
sion. Validation of key ﬁndings in human KRAS ade-
nocarcinomas identiﬁed several dominant
immunosuppressive mechanisms employed by KRAS
tumors. These mechanisms include spatiotemporal
organization of immune cells (T cell exclusion/inclu-
sion, MDSCs, Macrophages), expression of speciﬁc co-
inhibitory checkpoints (PD1-PD-L1, LAG-3, TIM-3,
TIGIT), and additional components of T cell suppres-
sion (IDO, Arginase, Tregs). Identiﬁcation of concur-
rent dominant immune suppressive mechanisms
employed by KRAS tumors has allowed us to employ
rationally guided effective combination therapeutics,
which are being tested in exploratory trials in pre-
clinical models, together with immunomodulatory ac-
tion of conventional standard of care chemotherapy
and radiation therapy. Our approach is in line with
recent success of combination immunotherapies in
melanoma and colon cancer, and could impact the
selection of immunotherapies for treating mutant
KRAS NSCLC patients in the clinic.
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Background: The mutation proﬁle of many cancer-
related genes in the Mexican population of patients with
non-small cell lung cancer (NSCLC) remains largely un-
explored and also their relationship to many clinical
features of the patients. Next Generation Sequencing
(NGS) allows multiplexing for sequencing several genes
with higher sensitivity than other techniques and it is
increasingly applied in clinical research. Hypothesis: The
population of Mexican NSCLC patients presents a speciﬁc
mutation proﬁle in cancer-related genes that can be
better characterized by targeted NGS than by PCR and
may be related to clinical characteristics.
Objectives: To detect the presence of somatic mutations
by targeted NGS and PCR in Mexican patients with
NSCLC and ﬁnd its association with clinicopathological
features.Methods: Overall 31 tumor biopsies of Mexican patients
with NSCLC were analyzed. DNA was extracted from
biopsies using the Wizard Genomic DNA kit. DNA con-
centration was determined by Qubit. Quality control was
performed with the FFPE QC kit for formalin-ﬁxed,
parafﬁn-embedded samples. Genomic libraries were
constructed using the TruSeq Cancer Panel comprising
212 amplicons of 48 genes. Sequences were obtained in
a MiSeq sequencer. EFGR mutations were analyzed
alternatively by using real time PCR using the Rotor-
Gene Q and the Scorpions and ARMS technologies.
Results: We found mutations in 19 cancer-related
genes speciﬁc for the Mexican population. In 37% of
cases we found mutations in the EGFR gene, in exon 19
(17%), exon 21 (13%) and two rare mutations in exons
2 and 3. We found a correlation for the diagnosis of
mutations in the EGFR gene by PCR and NGS in seven
patients. EGFR mutations were detected in four patients
by NGS that were not detected by PCR. Additional
mutations were found mainly in TP53 in 12 patients
(40%), followed by mutations in the genes GNAQ
(33%), HNF1A (16%), VHL (13%) and KRAS (10%).
Several other mutations were detected in minor fre-
quencies i.e. 6% for CTNNB1, FGFR2, MET and
SMARCB1 and 3% of the cases for APC, BRAF, CDH1,
ERBB2, FGFR3, GNAS, PTEN and RB1. The clinicopath-
ological characteristics of the patients were a median
age of 65 years in a range of 37-82 years, 93% of
patients had adenocarcinoma with 34% of mixed sub-
type, 23% acinar, 17% poorly differentiated, 13% solid,
10% lepidic and 3% papilar. Metastatic NSCLC was
detected in 53% of the patients, mainly in bones and
brain (33%). Overall 70% were female, 55% were
exposed to wood-smoke and 41% were smokers.
The performance status of the patients was predomi-
nantly ECOG1 with 78%. Most patients (76%) were
diagnosed at a disease stage IV while 24% presented
stage IIIB. Treatment was established according the
mutational status of the patients, 60% was treated with
chemotherapy: Cisplatin-Paclitaxel (30%), Pemetrexed-
Carboplatin (17%), Gemcitabine-Carboplatin (9%) and
Vinorelbine-Cisplatin (4%). Tyrosine kinase inhibitor
(TKI) treatment consisted of Erlotinib (17%), Geﬁtinib
(13%) and Afatinib (10%). Concerning the relationship
with clinical characteristics, 91% of the EGFR mutations
appeared in patients over 60 years of age (p 0.02).
Patients with EGFR mutations, particularly exon 19
deletions (83%) responded to TKIs either as partial
response (50%) or stable disease (33%) (p 0.024). The
presence of EGFR exon 19 deletions were associated
with metastatic NSCLC, with bone and brain metastases
as the most common secondary localization of disease
(p 0.044).
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mutation proﬁle with alterations in several cancer-
related genes mainly in EGFR, TP53, GNAQ, HNF1A, VHL
and KRAS. The NGS technology showed greater sensi-
tivity than PCR to detect relevant mutations in NSCLC.
Several mutations found in high incidence in this study
could become relevant targets for novel targeted thera-
pies in NSCLC.
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Double strand RNA (dsRNA) species were previously
thought to be a ‘junk DNA’ equivalent are related to
endogenous retroviral elements (ERV) inserted into
the human genome. Genomic integration sites and
blocking of these processes have been well docu-
mented in HIV and Hepatitis C related diseases. Viral
integration into human genome has been shown in a
range of solid tumors, but mechanisms less under-
stood. The detection of dsRNA in the research setting
has been largely limited to cell line models and
controlled transfections. To better characterize func-
tion signiﬁcance of ERV and interactions at the cellular
level, we outline efforts to detect and quantify such
viral genomic elements with a focus on archival clin-
ical samples in the commonly stored parafﬁn block.
Tissue blocks issues with clinical and biochemical
documented viral infection and associated viral cyto-
pathic changes were selected from the Department of
Pathology and Biorepository and standard 4 micron
sections were prepared. Two (2) commercially avail-
able antibodies raised to dsRNA fragments (J2 and K1
antibodies) were directly compared by chromogenic
and immunoﬂuorescent methods. In addition, down-
stream biomarkers as identiﬁed by literature searches
include RIG-1 and IRF 7 as moderate probable success
and MDA-5 and STAT 1 as higher level success.
Correlative analysis of downstream pathway markers
with labeling results of dsRNA antibodies suffers from
lack of sensitive measures of dsRNA fragments as
opposed to the downstream cellular pathway markers.
This lack of concordance likely reﬂects the short
nature of dsRNAs in decade old parafﬁn tissue and/or
differences in abundance. Future work will focus on
developing more sensitive probes or IF probe signal
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Background: Recurrence and lung cancer mortality in
resected, early stage lung cancer is likely due to the
presence of micro-metastatic disease not detected
during surgery or the pre-surgical assessment. The
likelihood of such latent disease increases with higher
stages and thus treatment with adjuvant therapy is
currently determined by pathological stage. However,
signiﬁcant recurrent disease and cancer-related
mortality even in stage I patients suggest that path-
ological stage alone does not adequately identify
resected patients that could beneﬁt from further
treatment. Tumor molecular features can improve
stratiﬁcation of patients for increased risk of distant
recurrence.
Methods: Formalin-ﬁxed surgical samples from 318
stage I and II lung adenocarcinoma patients, treated
with surgery alone, were examined for the expres-
sion of 31 proliferation genes (CCP score) by multi-
plex, quantitative RT-PCR. A prognostic score (PS)
was calculated from pathological stage and the CCP
score. The added prognostic value of the CCP score
for the prediction of ﬁve–year distant recurrence-free
survival and ﬁve-year cancer-speciﬁc survival was
tested in Cox proportional hazards regression models
with adjustment for clinical parameters. Estimates of
disease-free survival and cancer-speciﬁc survival
were calculated by the Kaplan-Meier method.
Results: Among 289 samples with successful expres-
sion analysis, 85 had developed a distant recurrence
at ﬁve years post-surgery. After adjustment for age,
gender, tumor size and pleural invasion, pathological
stage (HR 2.28, 95%CI 1.16-4.50 for IA vs IB,
p¼0.0015) and the CCP score (HR 1.62 per IQR, 95%
CI 1.15-2.29, p¼0.0055) were independent predictors
of distant recurrence and as well as for cancer-
speciﬁc survival [pathological stage (HR 1.72, 95%CI
0.93-3.17 for IA vs IB, p¼0.024), CCP score (HR 1.40
per IQR, 95%CI 1.03-1.90, p¼0.031)]. The prognostic
score was a better predictor of distant recurrence
than pathological stage alone (PS: HR 2.22 95%CI
1.11-4.44, p¼0.023, stage: HR 1.70 95%CI 0.86-3.35
